The efficacy of benzydamine on cancer treatment-induced oral mucositis: A systematic review of randomised controlled trials
Abstract
Objectives: Mucositis is a well-known complication of oncological therapies, severely affecting the quality of life of patients. Benzydamine appears to be a promising option for the treatment of this condition, particularly in the management of oral mucositis. We can learn more about the potential use of benzydamine for oral mucositis by examining the available published research and what we know from clinical trials that have used this agent. This systematic review aims to evaluate the efficacy of benzydamine for the prevention and treatment of oral mucositis induced by cancer therapy through Randomized Controlled Trials.
Methods: A systematic literature review was performed across seven databases. After screening, this systematic review included nine articles that had been published between 2013 and 2023. The review was conducted in accordance with the Cochrane guidelines (2023). Bias risk is assessed using the Cochrane Collaboration Risk of Bias Assessment Tool. The studies differed in the number of participants, from 26 to 120, giving a total of 593 participants analyzed. The articles in the studies used Benzydamine, herbal formulation, sodium bicarbonate, povidone-iodine, and low-level laser.
Results: Results showed that benzydamine was effective to varying extents. Several studies provided statistically important improvements while others showed no statistically important variations.
Conclusions: This extensive literature review and clinical study offer insight into how benzydamine may work in the management of oral mucositis.
Keywords
Ethical Statement
References
- 1. Liu YQ, Wang XL, He DH, Cheng YX. Protection against chemotherapy- and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals. Phytomedicine. 2021;80:153402. doi: 10.1016/j.phymed.2020.153402.
- 2. Toro López JR. Chemotherapy and radiotherapy: Could they contribute to the development of new tumors and metastases? Life Res. 2024;7(1)5. doi: 10.53388/lr20240005.
- 3. Zhang QY, Wang FX, Jia KK, Kong LD. Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects. Front Pharmacol. 2018;9:1253. doi: 10.3389/fphar.2018.01253.
- 4. Lu Y, Luo X, Yang D, et al. Effects of probiotic supplementation on related side effects after chemoradiotherapy in cancer patients. Front Oncol. 2022;12:1032145. doi: 10.3389/fonc.2022.1032145.
- 5. O'Reilly M, Mellotte G, Ryan B, O'Connor A. Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis. 2020;11:2040622320970354. doi: 10.1177/2040622320970354.
- 6. Alvariño-Martín C, Sarrión-Pérez MG. Prevention and treatment of oral mucositis in patients receiving chemotherapy. J Clin Exp Dent. 2014;6(1):e74-80. doi: 10.4317/jced.51313.
- 7. Nicolatou-Galitis O, Sarri T, Bowen J, et al; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3179-3189. doi: 10.1007/s00520-013-1847-y.
- 8. Peng TR, Tsai FP, Wu TW. Effects of various treatments for preventing oral mucositis in cancer patients: A network meta-analysis. PLoS One. 2022;17(12):e0278102. doi: 10.1371/journal.pone.0278102
Details
Primary Language
English
Subjects
Clinical Oncology
Journal Section
Research Article
Authors
Dilek Gümüş
*
0000-0002-5338-9377
Türkiye
Zeynep Yılmaz
0000-0001-7596-9041
Türkiye
Fuzuli Tuğrul
0000-0001-9724-253X
Türkiye
Early Pub Date
May 29, 2025
Publication Date
July 4, 2025
Submission Date
December 23, 2024
Acceptance Date
May 21, 2025
Published in Issue
Year 2025 Volume: 11 Number: 4